Across TCGA pan-cancer cohorts, ANKFY1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKFY1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANKFY1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKFY1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where ANKFY1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.861	0.520	<.001	96	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →
GBM	DFS	Tertile	All	0.606	0.783	.023	2	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	2	view →
LSCC	DFS	Quartile	II,III,IV	0.809	1.000	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ANKFY1 tumor-vs-normal RNA expression · all ANKFY1 data types